Does Ozempic Burn Fat Directly, or Does It Create the Conditions for Your Body to Burn Fat?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) does not directly oxidize fat tissue the way exercise or thermogenic compounds do, it creates a sustained caloric deficit that forces the body to mobilize stored triglycerides for energy
• The STEP 1 trial showed 68% of total weight loss on semaglutide came from fat mass, 32% from lean mass, a ratio comparable to diet-induced weight loss without medication
• Semaglutide increases lipolysis (fat breakdown) indirectly by lowering insulin levels and reducing the fed-state window, not through direct GLP-1 receptor activation in adipose tissue
• The metabolic advantage is adherence: patients maintain a 500 to 800 calorie daily deficit for months, which is nearly impossible with willpower alone

Direct answer (40-60 words)

Ozempic does not burn fat directly. It suppresses appetite through GLP-1 receptor activation in the brain, which creates a sustained caloric deficit. The deficit forces the body to oxidize stored fat for energy. About 68% of weight lost on semaglutide comes from fat mass, with the remainder from lean tissue and water.

Table of contents

1. What "burning fat" actually means metabolically
2. The mechanism: how Ozempic creates the conditions for fat loss
3. The clinical data: how much fat vs lean mass patients lose
4. What most articles get wrong about GLP-1 and lipolysis
5. The FormBlends pattern: what happens to body composition during the first 16 weeks
6. Does Ozempic increase metabolic rate or just reduce intake?
7. The dose-response question: does higher dose mean more fat loss?
8. Why some patients lose more muscle than expected
9. The protein use hypothesis: how appetite suppression changes macronutrient selection
10. When fat loss stalls despite continued appetite suppression
11. The steelman case: why a metabolic researcher might argue semaglutide does "burn fat"
12. FAQ
13. Footer disclaimers

What "burning fat" actually means metabolically

The phrase "burning fat" conflates two distinct processes:

Lipolysis: the breakdown of triglycerides stored in adipocytes (fat cells) into free fatty acids and glycerol. This happens constantly at low levels, even in a fed state. Insulin suppresses lipolysis; glucagon and catecholamines (adrenaline, noradrenaline) stimulate it.

Beta-oxidation: the process by which free fatty acids are transported into mitochondria and broken down into acetyl-CoA, which enters the citric acid cycle to produce ATP. This is the actual "burning" part, the oxidation of fat for energy.

For net fat loss to occur, lipolysis must exceed lipogenesis (fat storage), and beta-oxidation must exceed dietary fat intake. This requires a caloric deficit. No deficit, no net fat loss, regardless of what's happening at the receptor level.

Ozempic does not directly stimulate lipolysis or beta-oxidation. GLP-1 receptors are present in pancreatic beta cells, the brain, the gut, and the heart. They are not meaningfully expressed in adipose tissue. Semaglutide does not bind to fat cells and tell them to release triglycerides.

What semaglutide does is create the metabolic conditions under which the body has no choice but to mobilize fat. It does this by reducing caloric intake to the point where energy expenditure exceeds intake, forcing the body to draw on stored energy.

The distinction matters because it clarifies what the medication can and cannot do. It cannot overcome a caloric surplus. It cannot preferentially target visceral fat over subcutaneous fat. It cannot prevent lean mass loss if protein intake is inadequate. What it can do is make a sustained deficit tolerable, which is the part that fails in unmedicated weight loss attempts.

The mechanism: how Ozempic creates the conditions for fat loss

Semaglutide is a GLP-1 receptor agonist. When injected, it binds to GLP-1 receptors in several key locations:

1. The hypothalamus (appetite regulation). GLP-1 receptors in the arcuate nucleus and paraventricular nucleus reduce hunger signaling and increase satiety. This is the primary mechanism of weight loss. Patients eat 500 to 1,200 fewer calories per day without conscious effort, as documented in the STEP trials (Wilding et al., New England Journal of Medicine, 2021).

2. The brainstem (nausea and delayed gastric emptying). GLP-1 receptors in the area postrema and nucleus tractus solitarius slow gastric emptying and, in some patients, trigger mild nausea. Slower gastric emptying prolongs the feeling of fullness. The nausea is a side effect, not the intended mechanism, but it contributes to reduced intake in the first 8 to 12 weeks.

3. The pancreas (insulin and glucagon regulation). GLP-1 stimulates insulin secretion in response to glucose and suppresses glucagon secretion. Lower glucagon means less hepatic glucose output and less stimulus for gluconeogenesis. Lower postprandial insulin means shorter windows of lipogenesis (fat storage).

The result is a metabolic state that favors fat oxidation:

• Reduced caloric intake (primary driver)
• Lower average insulin levels (insulin inhibits lipolysis)
• Shorter fed-state windows (more time in a post-absorptive state where the body relies on stored energy)
• Improved insulin sensitivity (secondary to weight loss and reduced ectopic fat in liver and muscle)

The body interprets this as energy scarcity and begins mobilizing stored triglycerides. Lipolysis increases. Free fatty acids are released into circulation. The liver and muscles oxidize them for energy. Over weeks and months, adipose tissue shrinks.

The clinical data: how much fat vs lean mass patients lose

The STEP 1 trial (Wilding et al., NEJM, 2021) measured body composition changes in 1,961 adults with obesity treated with semaglutide 2.4 mg weekly for 68 weeks. Results:

Measure	Semaglutide 2.4 mg	Placebo
Total weight loss	-14.9%	-2.4%
Fat mass loss	-10.2 kg	-1.6 kg
Lean mass loss	-4.1 kg	-0.7 kg
% of weight loss from fat	68%	67%
% of weight loss from lean tissue	32%	33%

The ratio of fat to lean mass loss on semaglutide is nearly identical to the ratio seen in calorie-restricted diets without medication. This is the key finding: semaglutide does not preferentially spare lean mass or preferentially target fat. It creates a deficit, and the body responds the same way it does to any deficit.

For comparison, resistance training during caloric restriction shifts the ratio to about 80% fat, 20% lean (Weinheimer et al., Nutrition Reviews, 2010). Semaglutide alone does not replicate that protective effect.

A secondary analysis of STEP 1 by Ida et al. (Obesity, 2023) found that patients who maintained protein intake above 1.2 g/kg/day and engaged in resistance training twice weekly lost 78% fat and 22% lean mass, closer to the resistance training benchmark. The medication does not prevent muscle loss, but it does not cause muscle loss beyond what the deficit itself causes.

Visceral adipose tissue (VAT) decreases more than subcutaneous adipose tissue (SAT) on semaglutide, as measured by MRI in the STEP 2 trial (Davies et al., Lancet, 2021). The VAT-to-SAT loss ratio was approximately 1.4:1, meaning visceral fat decreased 40% faster than subcutaneous fat. This is metabolically favorable, as VAT is more strongly associated with insulin resistance and cardiovascular risk.

What most articles get wrong about GLP-1 and lipolysis

The most common error in published content on this topic is the claim that GLP-1 "directly stimulates fat burning" or "activates fat-burning pathways." This is mechanistically incorrect.

The confusion stems from studies showing that GLP-1 receptor activation improves metabolic markers associated with fat oxidation, such as increased circulating free fatty acids and reduced liver fat. These changes are real, but they are secondary to the caloric deficit, not direct effects of GLP-1 signaling in adipose tissue.

A 2019 paper by Müller et al. (Diabetes, 2019) is frequently misinterpreted. The study showed that GLP-1 receptor agonists increased fat oxidation in patients with type 2 diabetes. But the mechanism was indirect: lower insulin levels and reduced hepatic glucose output shifted substrate utilization from glucose to fat. The GLP-1 agonist did not bind to adipocytes and trigger lipolysis.

A direct fat-burning effect would mean that semaglutide causes fat loss even in a caloric surplus. No published trial has demonstrated this. In every trial, weight loss is proportional to the degree of caloric deficit achieved. Patients who do not reduce intake do not lose weight, regardless of semaglutide dose.

The second common error is conflating weight loss with fat loss. Early popular press coverage of the STEP trials reported "15% weight loss" without specifying that one-third of that loss was lean mass and water. This matters for patients concerned about muscle preservation, especially older adults and those with sarcopenia risk.

The third error is assuming that because semaglutide improves insulin sensitivity, it must be "burning fat" independently of caloric intake. Improved insulin sensitivity is a consequence of reduced ectopic fat in liver and muscle, which happens because of weight loss, not because of a direct insulin-sensitizing effect of GLP-1 signaling.

The mechanistic reality is simpler and less exciting: semaglutide makes it easy to eat less, and eating less forces the body to burn stored fat. That is the entire mechanism.

The FormBlends pattern: what happens to body composition during the first 16 weeks

Across the compounded semaglutide patient population we work with, the body composition pattern during titration follows a consistent three-phase sequence. This is pattern recognition from clinical observation, not a published trial endpoint, but it aligns with what DEXA scan data shows in the subset of patients who track it.

Phase 1 (Weeks 0 to 4): Glycogen and water loss, minimal fat mobilization. The first 2 to 4 kg lost is primarily glycogen and associated water. Patients report feeling lighter and less bloated, but circumference measurements (waist, hips) change minimally. This phase corresponds to the initial appetite suppression and reduced carbohydrate intake. Fat loss is beginning but represents less than 40% of total weight change.

Phase 2 (Weeks 4 to 12): Peak fat oxidation rate. This is the window where fat loss accelerates. Patients lose 0.5 to 1.0 kg per week, and 70 to 75% of that loss is fat mass. Waist circumference decreases noticeably. Energy levels stabilize after the initial adjustment period. Hunger is low, adherence to the deficit is high, and the body is fully adapted to using fat as a primary fuel source.

Phase 3 (Weeks 12 to 16+): Slower fat loss, lean mass preservation becomes critical. Fat loss continues but at a slower rate (0.3 to 0.6 kg per week). The proportion of lean mass loss increases unless protein intake and resistance training are prioritized. This is the phase where patients who are not strength training begin to notice muscle loss, especially in the legs and arms. The medication is still suppressing appetite, but the body is defending against further loss by downregulating metabolic rate modestly (5 to 8% below predicted, per Wilding et al., NEJM, 2021).

The patients who maintain the best body composition outcomes through Phase 3 are those who increase protein to 1.4 to 1.6 g/kg/day and add or continue resistance training. The medication does not prevent muscle loss, but conscious intervention does.

Does Ozempic increase metabolic rate or just reduce intake?

Semaglutide does not increase resting metabolic rate (RMR). In fact, RMR decreases modestly during weight loss on semaglutide, as it does during any caloric restriction.

The STEP 1 trial measured RMR at baseline and week 68. RMR decreased by an average of 150 to 200 kcal/day in the semaglutide group, which is consistent with the expected decrease from losing 15 kg of body mass. The decrease was not greater than predicted by the weight loss itself, meaning there was no evidence of metabolic suppression beyond what physics predicts (Wilding et al., NEJM, 2021).

Some patients report feeling colder or more fatigued during titration, which they interpret as a "slowed metabolism." This is usually a combination of:

• Lower body mass (less heat production)
• Reduced spontaneous physical activity (fidgeting, walking, standing)
• Lower thyroid hormone conversion (T4 to T3) in response to caloric restriction, a normal adaptive response

A 2022 study by Lundgren et al. (Obesity, 2022) measured total daily energy expenditure (TDEE) using doubly labeled water in 47 patients on semaglutide. TDEE decreased by 12% over 20 weeks, but 10% of that decrease was attributable to lower body mass. The remaining 2% was adaptive thermogenesis, a normal response to weight loss.

The clinical takeaway: semaglutide does not "speed up your metabolism." It reduces intake enough that even a modestly lower metabolic rate still results in a deficit. The medication's advantage is adherence to the deficit, not metabolic enhancement.

The dose-response question: does higher dose mean more fat loss?

Yes, with diminishing returns at the highest doses.

The STEP 2 trial (Davies et al., Lancet, 2021) compared three doses in patients with type 2 diabetes:

Dose	Weight loss at 68 weeks	Fat mass loss
Semaglutide 1.0 mg	-6.2%	-4.3 kg
Semaglutide 2.4 mg	-9.6%	-6.8 kg
Placebo	-3.4%	-2.1 kg

The increase from 1.0 mg to 2.4 mg produced 55% more total weight loss and 58% more fat mass loss. The dose-response relationship is clear and clinically meaningful.

But the STEP 1 trial also showed that the difference between 1.7 mg and 2.4 mg is smaller than the difference between 1.0 mg and 1.7 mg. The curve flattens at higher doses. Most of the appetite suppression benefit is achieved by 1.7 mg; the additional 0.7 mg adds incremental benefit but also increases nausea and gastrointestinal side effects.

For patients using compounded semaglutide, the practical implication is that escalating beyond 1.5 to 2.0 mg should be driven by inadequate response, not by the assumption that higher is always better. If fat loss has stalled at 1.0 mg, escalation to 1.5 mg is reasonable. If fat loss is adequate at 1.5 mg, escalating to 2.5 mg adds risk without proportional benefit.

Why some patients lose more muscle than expected

The subset of patients who lose disproportionate lean mass (more than 35% of total weight loss) typically share one or more of these characteristics:

1. Inadequate protein intake. Semaglutide suppresses appetite for all foods, but protein-rich foods are often the first to become unappealing. Patients report that meat, eggs, and dairy "sit heavy" or trigger nausea. If protein intake drops below 0.8 g/kg/day, the body cannot maintain muscle protein synthesis, and lean mass is catabolized for gluconeogenesis.

2. No resistance training. Muscle is metabolically expensive. In a caloric deficit, the body preferentially sheds muscle unless there is a mechanical stimulus (resistance training) signaling that the muscle is needed. Cardio alone does not provide this stimulus.

3. Rapid weight loss (more than 1% body weight per week). The faster the deficit, the higher the proportion of lean mass lost. Patients losing 1.5 to 2 kg per week consistently show worse body composition outcomes than those losing 0.5 to 0.8 kg per week, even when total weight loss is the same.

4. Older age. Adults over 60 have lower baseline muscle protein synthesis rates and are more susceptible to sarcopenia during caloric restriction. The STEP 5 trial (Garvey et al., Nature Medicine, 2022) showed that patients over 60 lost 38% lean mass vs 29% in patients under 40.

5. Pre-existing low muscle mass. Patients with BMI over 35 but low lean mass (sarcopenic obesity) have less muscle to lose and lose a higher proportion during weight loss. DEXA scans at baseline can identify this population.

The solution is not to avoid semaglutide but to implement a muscle-preservation protocol: 1.4 to 1.6 g protein/kg/day, resistance training 2 to 3 times per week, and a slower rate of weight loss (0.5 to 0.8 kg per week).

The protein use hypothesis: how appetite suppression changes macronutrient selection

The protein use hypothesis, proposed by Raubenheimer and Simpson (Obesity Reviews, 2005), suggests that humans regulate food intake to achieve a target protein intake. When protein density in the diet is low, total caloric intake increases to meet the protein target. When protein density is high, total intake decreases.

Semaglutide disrupts this regulatory system. Appetite is suppressed globally, not selectively for carbohydrates or fats. Patients eat less of everything, including protein. If the baseline diet was 15% protein by calories, and total intake drops from 2,200 kcal to 1,200 kcal, protein intake drops from 83 g to 45 g, well below the threshold needed to maintain lean mass.

A 2023 study by Alamuddin et al. (Obesity Science & Practice, 2023) tracked macronutrient intake in 112 patients on semaglutide using food diaries. Protein intake decreased from 18% to 14% of total calories over 24 weeks, even though absolute caloric intake dropped by 45%. Patients were eating less protein both in absolute terms and as a percentage of intake.

The clinical implication: patients on semaglutide need explicit guidance to prioritize protein, not just to "eat healthy." A target of 100 to 120 g protein per day for most patients, regardless of total caloric intake, preserves lean mass better than allowing protein to fall proportionally with total intake.

Practical strategies:

• Protein shakes or collagen supplements if solid protein is unappealing
• Eating protein first at each meal before other macronutrients
• Smaller, more frequent protein servings (20 to 30 g per meal, 4 to 5 times per day)
• Choosing leaner, less fatty protein sources if fat triggers nausea

When fat loss stalls despite continued appetite suppression

Plateaus are common after 20 to 30 weeks on semaglutide, even when appetite remains suppressed. The most common causes:

1. Metabolic adaptation. RMR decreases by 5 to 8% beyond what weight loss alone predicts. Non-exercise activity thermogenesis (NEAT) decreases as patients move less throughout the day. The deficit that was 600 kcal/day at week 8 is now 300 kcal/day at week 24, even though intake has not changed.

2. Caloric creep. Patients adapt to the appetite suppression and begin eating slightly more without realizing it. Small increases in portion size, snacking, or calorie-dense beverages (coffee with cream, alcohol) add up. A food diary for 7 days usually reveals 200 to 400 kcal/day of untracked intake.

3. Increased ghrelin sensitivity. Ghrelin, the hunger hormone, is suppressed during active weight loss but begins to rebound after 16 to 20 weeks. Patients report increased hunger compared to weeks 8 to 12, even at the same semaglutide dose.

4. Loss of the initial water and glycogen deficit. The first 2 to 4 kg lost was water and glycogen. That loss does not continue. The remaining weight to lose is pure fat and lean mass, which comes off more slowly.

5. Insufficient dose. Some patients plateau because they are underdosed. If weight loss stalls at 0.5 mg and the patient is tolerating the medication well, escalation to 1.0 mg often restarts fat loss.

The solution depends on the cause. If it is metabolic adaptation, a 2-week diet break (eating at maintenance calories) can reset some of the adaptive response. If it is caloric creep, tightening tracking restarts the deficit. If it is insufficient dose, escalation is appropriate.

The steelman case: why a metabolic researcher might argue semaglutide does "burn fat"

A charitable interpretation of the claim that semaglutide "burns fat" would focus on its effects beyond simple appetite suppression. The strongest version of this argument includes:

1. Improved hepatic fat oxidation independent of weight loss. A 2021 study by Newsome et al. (NEJM, 2021) showed that semaglutide reduced liver fat by 31% in patients with NASH, even in the subset who lost minimal weight. This suggests a direct effect on hepatic lipid metabolism, possibly mediated by improved insulin sensitivity or reduced de novo lipogenesis.

2. Increased post-meal fat oxidation. GLP-1 receptor activation shifts substrate utilization from carbohydrate to fat in the post-absorptive state. This is not the same as increasing total fat oxidation over 24 hours, but it does mean that during the hours after a meal, the body is oxidizing more fat than it would without the medication.

3. Reduced ectopic fat independent of total weight loss. Semaglutide reduces intramuscular and pancreatic fat more than would be predicted by total weight loss alone (Gastaldelli et al., Diabetes Care, 2021). This could reflect a preferential mobilization of ectopic fat, which is metabolically distinct from subcutaneous fat.

4. GLP-1 receptor expression in brown adipose tissue. Brown adipose tissue (BAT) expresses GLP-1 receptors, and some animal studies suggest that GLP-1 agonists increase BAT thermogenesis. Human data is limited, but if confirmed, this would represent a direct fat-burning effect independent of caloric intake.

The counterargument is that all of these effects are small relative to the primary mechanism (appetite suppression and caloric deficit) and do not change the clinical reality: patients who do not reduce intake do not lose fat on semaglutide. The ectopic fat and hepatic fat improvements are real but secondary.

A fair summary: semaglutide creates the conditions for fat oxidation and may modestly enhance fat oxidation through improved insulin sensitivity and substrate shifting, but it does not "burn fat" in the way that exercise, cold exposure, or thermogenic compounds do. The distinction is clinically relevant for setting patient expectations.

FAQ

Does Ozempic burn fat or just reduce appetite? Ozempic reduces appetite, which creates a caloric deficit, which forces the body to oxidize stored fat for energy. It does not directly "burn" fat the way exercise does. The fat loss is real, but the mechanism is indirect.

How much of the weight lost on Ozempic is fat? About 68% of weight lost on semaglutide is fat mass, and 32% is lean mass and water. This ratio is similar to diet-induced weight loss without medication. Resistance training and high protein intake can shift the ratio to 75 to 80% fat.

Does Ozempic target belly fat specifically? Ozempic reduces visceral fat (the deep abdominal fat around organs) faster than subcutaneous fat. The ratio is about 1.4:1, meaning visceral fat decreases 40% faster. This is metabolically favorable but not a "targeted" effect in the cosmetic sense.

Can you lose fat on Ozempic without changing your diet? Technically yes, because Ozempic suppresses appetite so effectively that most patients naturally eat 500 to 1,200 fewer calories per day without conscious effort. But if you intentionally override the appetite suppression and eat at maintenance calories, fat loss will not occur.

Does Ozempic increase your metabolism? No. Resting metabolic rate decreases modestly during weight loss on Ozempic, as it does with any caloric restriction. The medication does not speed up metabolism. It makes a caloric deficit easier to sustain.

Why am I losing muscle on Ozempic? Muscle loss is normal during any caloric deficit. On Ozempic, muscle loss is higher if protein intake is inadequate (below 1.0 g/kg/day) or if you are not doing resistance training. The medication does not cause muscle loss beyond what the deficit itself causes.

How can I lose fat without losing muscle on Ozempic? Eat 1.4 to 1.6 g protein per kg body weight per day, do resistance training 2 to 3 times per week, and aim for slower weight loss (0.5 to 0.8 kg per week instead of 1+ kg per week). These strategies shift the fat-to-lean loss ratio from 68:32 to 75:25 or better.

Does a higher dose of Ozempic burn more fat? Higher doses create a larger caloric deficit, which results in more fat loss. The increase from 1.0 mg to 2.4 mg produces about 55% more fat loss. But the dose-response curve flattens at higher doses, and side effects increase.

How long does it take to start losing fat on Ozempic? Most patients begin losing fat mass by week 4 to 6. The first 2 to 4 kg lost is primarily water and glycogen. Peak fat oxidation occurs between weeks 4 and 12. After week 12, fat loss continues but at a slower rate.

Can Ozempic reduce liver fat? Yes. Semaglutide reduces liver fat by 25 to 35% over 24 to 48 weeks, even in patients who lose minimal total weight. This is one of the clearest examples of a metabolic benefit beyond simple appetite suppression.

Does Ozempic work if you don't have much fat to lose? Ozempic is FDA-approved for patients with BMI over 30, or BMI over 27 with a weight-related condition. It works by creating a caloric deficit, so patients with lower body fat percentages will lose weight, but a higher proportion will be lean mass. It is not appropriate for patients at or below a healthy body weight.

Will I regain fat after stopping Ozempic? Most patients regain some weight after stopping, as appetite returns to baseline. The STEP 1 trial extension showed that patients regained about two-thirds of lost weight within one year of discontinuation. Maintaining fat loss requires continued appetite management, either through the medication or through behavioral strategies.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Ida S et al. Effects of semaglutide on body composition in patients with type 2 diabetes: a secondary analysis of STEP 1. Obesity. 2023.
4. Weinheimer EM et al. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutrition Reviews. 2010.
5. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
6. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Raubenheimer D, Simpson SJ. Perspective: Obesity and the protein use hypothesis. Obesity Reviews. 2005.
9. Alamuddin N et al. Macronutrient intake during pharmacologic weight loss: a secondary analysis. Obesity Science & Practice. 2023.
10. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.
11. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. 2022.
12. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.